Sources and Structure
Punicic Acid is found in:
- Pomegranates at 63.5% total fatty acid profile, with another 14.2% possibly being isomers of Punicic Acid. As pomegranates contain slightly over 1% fatty acids on a wet weight basis, 300g of fresh pomegranate confers 3g Punicic acid (estimate)
- Trichosanthes kirilowii seeds, at 24.3% of the fatty acids by weight and 3g Punicic acid per 24.5g seeds
Punicic acid is named after its source, Pomegranates, which have the vernacular name of Punica granatum.
Punicic Acid is a conjugated linoleic acid molecule, but not one of the fatty acids referred to as supplemental CLA; typical Conjugated Linoleic Acid (CLA) supplements contain linoleic acid molecules with two double bonds in various locations; Punicic Acid contains a third double bond, is known as _cis_9, _trans_11, _cis_13, and is referred to as an 18:3 fatty acid rather than an 18:2 fatty acid (amount of carbons in the side chain: amount of double bonds). Structurally, it is the c9t11 Conjugated Linoleic Acid isomer with a cis double bond added on the side closer to the tail.
It is one of the main 5 18:3 conjugated linoleic acid molecules, with the others being alpha-eleostearic acid (cis9, trans11, trans13), jacaric acid (cis8,trans10,cis12), catalpic acid (9trans,11trans,13cis) and calendic acid (8trans,10trans,12cis).
Similar to Conjugated Linoleic Acid, Punicic acid may eventually refer to a category of 18:3 conjugated linoleic acids and may not be a single molecule; the above is the standard Punicic acid molecules found in Pomegranates
Ingestion of 3g Punicic acid for 28 days (via the seeds of Trichosanthes kirilowii) increases the content of Punicic acid in circulating phospholipids from negligible amounts to 0.34+/-16% of total lipids and similar study design, when replicated, led to an increase from negligible to 0.47+/-0.04%.
It was found in rats that Punicic acid, which is a c9t11c13 fatty acid, could be rapidly metabolized into circulating c9t11 conjugated linoleic acid, similar to another 18:3 fatty acid mentioned earlier, the c9t11t13 alpha-eleostearic acid. This, if replicated in humans, would mean some of the bioactivity of Punicic Acid is due to c9t11 CLA. A study designed with a 7 day adaptation period where participants were advised to not consume sources of CLA (ruminant foods) followed by 28 days punicic acid intervention (via Trichosanthes seeds) found that while the control group had CLA levels circulating from 0.05-0.06% of total fatty acids, the Punicic Acid intervention rose to 0.23+/-0.03% of total fatty acids (although Punicic acid itself was found, suggesting partial metabolism). This replicated the effects found in a previous phamacokinetic study noting higher than normal CLA levels, but did not control for dietary intake. It appears Punicic acid can incompletely get metabolized into c9t11 Conjugated Linoleic Acid
Punicic Acid can be metabolized into the lesser potent isomer of Conjugated Linoleic Acid known as c9t11
Obesity and Fat Mass
Punicic acid, via the seeds of Trichosanthes kirilowii, has been shown to increase lipid peroxidation via measurements of 8-iso-PGF2α; if motifs from Conjugated Linoleic Acid research are carried over (due to similar structures), this may be indicative of peroxisomal oxidation of Punicic acid and not actually indicative of lipid peroxidation. Regardless of the mechanisms, 28 days of ingesting 20.8g of the seeds (12.5g fatty acids with 3g Punicic Acid) daily, relative to control (sunflower seeds), increased urinary 8-iso-PGF2α by approximately 50% without influencing C-reactive protein or IL-6.
Inflammation and Immunology
Enterocolitis and the Intestines
In a rat model of Necrotizing Enterocolitis (NES), Pomegranate Seed Oil at 1.5% of the diet was able to suppress the occurrence of NES (from 61% to 26%) and normalizing inflammatory biomarkers (TNF-α and interleukins) were measured in the ileum.
Interactions with Lipid Metabolism
4 weeks of Pomegranate Oil supplementation (800mg, 72% Punicic Acid) has been shown to reduce triglycerides in hyperlipidemic adults from 3.45+/-1.56mmol/L to 2.75+/-1.40mmol/L (20% decrease) without significantly affecting body weight. Secondary to the lower triglycerides, a better ratio of HDL:TG was seen as HDL-C was nonsignificantly increased from baseline values. These effects were replicated by the same researcher(s) 2 years later, where 45 hyperlipidemic adults had similar decreases in TGs with exactly the same magnitude and variance.
A study done on healthy youth noted no influence on triglyceride levels, or any measured lipoprotein (HDL-C, LDL-C).
Appears to have the ability to reduce triglycerides, but I would not put too much faith into it due to the probability of rehashed data is higher than the probability of getting the exact same standard deviations in two independent trials
Interactions with Cancer
In vitro, Punicic acid appears to have the ability to inhibit breast cancer cell proliferation at 40uM, and did so in both an estrogen responsive and estrogen non-responsive cell line. In the cell lines of MDA-MB-231 and MDA-ERa7, proliferation was inhibited by 92% and 96% while apoptosis via a disrupted mitochondrial membrane potential via PKC was induced in 86% and 91% of these cell lines, respectively. These effects were secondary to Punicic acid's pro-oxidative effects, as these effects were abolished by 20uM Vitamin E tocotrienol incubation. Another study conducted found lower numbers (70-75% inhibition) at 50uM, and noted that the 18:3 conjugated fatty acid known as alpha-eleosteroic acid was more potent, fully inhibiting proliferation at 50uM of MDA-MB-231 and MCF-7 cell lines.
Interactions with Hormones
Punicic acid has been demonstrated to be an anti-estrogen on ERa with an IC50 of 7.2uM and on ERb with an IC50 of 8.8uM with slight preference towards the ERa subset. The IC50 values for ERa and ERb were 2.7-fold and 1.36-fold lower relative to resveratrol with similar potencies (Punicic acid being 0.0040-0.0067% as potent as 17β-estradiol on the receptor, Resveratrol being 0.0024-0.0029% as potent).
Punicic acid, at low concentrations (1.8-2uM) is able to activate both of the estrogen receptors while at higher doses (101uM and 80uM for ERa and ERb) antagonized both estrogen receptors. Thus Punicic acid may be a Selective Estrogen Receptor Modulator (SERM) compound.
Xanthigen is a brand name for fucoxanthin, a potential fat burning carotenoid from seaweed, with Pomegranate Seed Oil as a base; thus confering both the bioactivities of Punicic acid and Fucoxanthin. Fucoxanthin itself is implicated in fat loss, and human trials using Xanthigen have shown significant fat loss over time. In vitro, the two molecules show some degree of synergism in pro-fat loss effects.
Mechanisms of synergism, but no real estimate as to how much of fucoxanthin's benefits are enhanced by Punicic acid